Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Stock Information for BriaCell Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BriaCell Therapeutics Corp.

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
High?Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.